Roche (RHHBY.PK) said the pivotal Phase III study CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia, or CLL, survived their disease longer when treated with Rituxan compared to chemotherapy alone.
The company noted that new data from the Phase III CLL8 study showed that 84.1% of patients with previously untreated CLL who received Rituxan plus fludarabine and cyclophosphamide, or FC, were alive after more than three years of follow up compared to 79.0% of patients who received FC alone. However, the median survival has not yet been reached. After more than three years of follow up, patients who received Rituxan plus FC had a median progression-free survival of 51.8 months compared to 32.8 months for those who received FC alone.
For comments and feedback: editorial@rttnews.com